Hemispherx Biopharma, Inc.

AMEX: HEBHealthcare / Biotechnology / USA
5.08-0.2700-5.05%Vol 315 1151Y Perf -61.42%
Jun 14th, 2019 16:00
BID5.13 ASK5.17
Open5.51 Previous Close5.35
Pre-Market5.50 After-Trading5.15
 0.15 2.80%  0.07 1.38%
Target Price
- 
Analyst Rating
— 0.00
Potencial %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
100/100/100 
Value Ranking
 —    -
Insiders Value % 3/6/12M
100/100/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12M
100/100/100 
Income Ranking
 —    -
Market Cap (mil)10 
Earnings Rating
Buy
Price Range Ratio 52wk %
9.77 
Earnings Date
15th May 2019

Today's Price Range

5.015.63

52wk Range

4.0114.96

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Month
3 286.67%
3 Months
2 888.24%
6 Months
2 573.68%
1 Year
-61.42%
3 Years
284.85%
5 Years
1 398.53%

Name / TickerPriceChg.Chg.%
HEB5.08-0.2700-5.05
AAPL192.74-1.4100-0.73
GOOG1 085.35-3.4200-0.31
MSFT132.450.13000.10
XOM74.35-0.3300-0.44
WFC45.590.30000.66
JNJ140.09-0.6200-0.44
FB181.333.86002.18
GE10.23-0.0800-0.78
JPM109.820.28000.26
Earnings HistoryEstimateReportedSurprise %
Q04 2016--0.04-
Q02 2016--0.01-
Q01 2016--0.01-
Q04 2015--0.01-
Q03 2015--0.02-
Q02 2015--0.02-
Q01 2015--0.02-
Q04 2014--0.02-
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume315 115
Shares Outstanding (in ths.)1 966
Trades Count895
Dollar Volume1 367 548
Avg. Volume87 722
Avg. Weekly Volume577 798
Avg. Monthly Volume225 129
Avg. Quarterly Volume147 766
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
1 (100.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
0 (0.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Rating--Strong Buy
1.00

Hemispherx Biopharma, Inc.

Hemispherx Biopharma Inc is a US-based specialty pharmaceutical company. It is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune-based disorders. The products of the firm are Alferon N Injection and the experimental therapeutic Ampligen. Alferon N Injection is approved for a category of STD infection, and Ampligen represents a RNA being developed for viral diseases and disorders of the immune system. The sales revenue of the company is derived from the United States.

CEO: Thomas K. Equels

Teplephone: +1 215 988-0080

Address: 2117 SW Highway 484, Ocala 34473, FL, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

83%17%

Bearish Bullish

71%29%

Bearish Bullish

69%31%

News